{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-104144","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.048675+00:00","generated_at":"2026-05-15T13:41:19.420142+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IN8bio reports FY2025 net loss $19.4M; GBM trial shows 97% PFS improvement","bullets":["Net loss $19.4M ($4.44/share) vs $30.4M ($17.05/share) prior year; cash $27.1M vs $11.1M year-end 2024.","Updated GBM data: mPFS 13.0 months for DRI patients vs 6.6 months SOC (+97%); mOS not yet reached at 17.2+ months.","Closed initial $20.1M of $40.2M private placement; net proceeds $18.5M extend cash runway into H1 2027.","Kate Rochlin promoted to President and COO in February 2026.","Anticipates FDA guidance on regulatory pathway for GBM program by H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-104144","json":"https://secwatch.observer/filing/0001193125-26-104144.json","markdown":"https://secwatch.observer/filing/0001193125-26-104144.md","text":"https://secwatch.observer/filing/0001193125-26-104144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312526104144/0001193125-26-104144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312526104144/inab-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:41:19.420142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b96c74c13e7892f7a5e001acde43ff4ad9aec3ae","claim":"IN8BIO, INC. reported financial results for fourth quarter and fiscal year ended December 31, 2025.","evidence_excerpt":"On March 12, 2026, IN8bio, Inc. (the “Company”) issued a press release announcing its financial results for fourth quarter and fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312526104144/0001193125-26-104144-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and fiscal year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}